Puli's new product launch: China and the United States have reported that the precise administration

【 Puli New Product Launch 】 Both China and the United States have reported that the precise administration of linezolid dry suspension has been approved for market by the National Medical Products Administration. Puli Pharmaceutical's linezolid dry suspension has been approved for market by the National Medical Products Administration! Zhejiang Puli Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Hainan Puli Pharmaceutical Co., Ltd., recently received the drug registration approval for linezolid dry suspension issued by the National Medical Products Administration. The approved linezolid dry suspension is registered as a Class three chemical drug and is considered to have passed the consistency evaluation, which will have a positive impact on expanding the domestic market. The launch of this product further enriches Puli Pharmaceutical's anti infection product line and better meets clinical medication needs. At the same time, its dosage form is convenient to take, especially suitable for special populations such as children, the elderly, and those with swallowing difficulties, which will provide better choices for clinical medication. Introduction to Linezolid: Linezolid belongs to the oxazolidinone class of synthetic antibiotics and can be used to treat infections caused by aerobic gram-positive bacteria in newborns, children, and adults, including hospital acquired pneumonia, community-acquired pneumonia, complex skin and skin soft tissue infections, uncomplicated skin and skin soft tissue infections, and vancomycin resistant enterococcal infections (including associated bacteremia). Linezolid is a fully synthetic antibacterial drug that is an inhibitor of bacterial protein synthesis. It binds to the fiftyS subunit of ribosomes, inhibits mRNA ribosome binding, and prevents the formation of the seventyS initiation complex, thereby inhibiting bacterial protein synthesis in the early stages of translation. Due to the unique site and mode of action of this drug, there is no cross resistance between it and other protein synthesis inhibitors, and it is not easy to induce bacterial resistance in vitro. The mechanism of action of linezolid is rapid and complete oral absorption, with an absolute bioavailability of about one hundred%. Therefore, in patients with stable clinical symptoms, the route of administration can be changed from intravenous injection to oral administration without the need to adjust the dosage. The presence of food does not affect its absorption, and its combination with antacids such as magnesium hydroxide and aluminum hydroxide has no effect on oral absorption. It has good tissue permeability and does not require dose adjustment for elderly patients, patients with mild to moderate liver or kidney dysfunction. There is a significant increase in demand for oral formulations of linezolid in clinical practice. The main dosage forms of linezolid are injections, tablets, and dry suspensions. Linalidomide glucose injection and Linalidomide tablets have been collected collectively, while dry suspensions have not been collected yet. According to data from MineNet, the oral formulation of linezolid has gradually increased in recent years, with sales of two hundred and nineteen million yuan, two hundred and forty million yuan, and two hundred and fifty-two million yuan in urban public hospitals from two thousand twenty-one to two thousand twenty-three, respectively. In terms of sales volume, the growth of linezolid oral formulations is more significant, with six.twenty-eight million tablets, eight.four million tablets, and ten.twelve million tablets from two thousand twenty-one to two thousand twenty-three, respectively, maintaining a growth rate of over twenty-five% in the past two years. In addition, Puli Pharmaceutical's linezolid dry suspension is currently the third of its kind to pass consistency evaluation (currently only three have been evaluated), indicating a good competitive landscape in the future. The Linezolid Dry Suspension of Puli Pharmaceutical, which is a product of both China and the United States, shares the same production line and quality standards in the domestic and American markets